TODAY'S PAPER
62° Good Morning
62° Good Morning
Business

Chembio's combo diagnostic test wins approval in Brazil 

The test scans patients for three diseases - Zika, dengue and chikungunya - that are all spread by mosquitoes and have similar symptoms.

Chembio Diagnostic Systems of Medford, seen in October

Chembio Diagnostic Systems of Medford, seen in October 2016. The company won approval from Brazil's health agency for its combination diagnostic test. Photo Credit: Barry Sloan

Chembio Diagnostics Inc. announced Tuesday its combination test for Zika, dengue and chikungunya has been approved by Brazil’s health regulatory agency.

The Medford-based manufacturer said Agencia Nacional de Vigilancia Sanitaria (ANVISA) has given the OK for use of the new blood test, which was developed with another Brazilian government agency, Bio-Manguinhos/Fiocruz.

“Brazil faces a complex epidemiological scenario, characterized by simultaneous circulation of three arboviruses: Zika, dengue and chikungunya,” said Chembio CEO John J. Sperzel. All three diseases are spread by mosquitoes.

“Co-circulation hampers clinical differential diagnoses, as those arboviruses share common signs and symptoms,” he said. “This ANVISA approval paves the way for commercialization in Brazil” of the new point-of-care test.

Chembio has been working with Brazilian officials for some time to combat the spread of Zika and other illnesses in South America’s largest nation.

Chembio shares closed up Tuesday 27 cents, or 4 percent, to $6.60 on the Nasdaq Stock Market.

Comments

We're revamping our Comments section. Learn more and share your input.

More news